Muted Q1 For Aurobindo But Outlook Firm; Don’t Expect ‘Exotic’ M&A
Aurobindo Pharma reported a subdued Q1 but investors remained upbeat on the firm’s prospects as it transitions to a larger complex generics play. The company also emphasized its “disciplined” M&A approach; it has no interest in chasing “exotic” deals.
You may also be interested in...
Aurobindo is betting big, buying certain portions of Sandoz’s US portfolio in a deal potentially worth $1bn. The acquisition positions the Indian firm in the top league in the overall US generics space by Rx and also segments like dermatology, but much could depend on how effectively Aurobindo delivers on value creation potential amid ongoing price pressures.
Intas Pharmaceuticals of India has acquired certain Teva assets in Europe – a transaction that is expected to give the unlisted Indian group significantly expanded scale in the region.
Expert outlines how pharma can create resilient and secure supply chains and some benefits of localization.